Carotuximab (TRC105)

DRUG3 trials

Sponsors

Tracon Pharmaceuticals Inc.

Conditions

Carcinoma, Non-Small-Cell LungFallopian Tube CarcinomaHepatocellular CarcinomaPrimary Peritoneal CarcinomaRecurrent Ovarian Cancer

Phase 1

Trial of TRC105 and Sorafenib in Patients With HCC

CompletedNCT02560779

Tracon Pharmaceuticals Inc.Hepatocellular Carcinoma

Start: 2016-11-30End: 2019-08-31Updated: 2020-07-17

Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

CompletedNCT03181308

Tracon Pharmaceuticals Inc.Carcinoma, Non-Small-Cell Lung

Start: 2017-11-09End: 2019-07-22Updated: 2020-06-24

Phase 2

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

CompletedNCT01381861

Tracon Pharmaceuticals Inc.Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Cancer

Start: 2011-07-31End: 2013-12-31Updated: 2019-03-05

Related Papers

Abstract 291: Synergistic inhibition of cancer invasion and metastasis by combined anti-PD1-TRC105-mediated Endoglin targeting on cancer-associated fibroblasts and endothelial cells

Experimental and Molecular Therapeutics2019-07-01

Abstract 291: Synergistic inhibition of cancer invasion and metastasis by combined anti-PD1-TRC105-mediated Endoglin targeting on cancer-associated fibroblasts and endothelial cells

Cancer Research2019-07-01